New drug combo trial aims to control aggressive blood disorder
NCT ID NCT03564873
Summary
This study is testing the safety and effectiveness of combining two drugs, omacetaxine and azacitidine, for people with high-grade myelodysplastic syndromes (MDS), a serious bone marrow disorder. The goal is to find the best dose and see if the combination can control the disease, shrink it, and help patients live longer. The trial is for adults who have not yet been treated for this type of MDS, as well as a small group whose disease has returned or not responded to prior therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universtiy of Colorado Denver
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.